Clinical Trials
28 trialsCD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
National Institutes of Health Clinical Center (CC)
Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)
Columbia University
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Lyell Immunopharma, Inc.
Cord Blood Transplantation in Children and Young Adults With Blood Cancer
Memorial Sloan Kettering Cancer Center
EPCOREâ„¢FL-2
Genmab
VIWA-1
University of Ulm
REFRACT
University of Birmingham
QUADvance
AvenCell Therapeutics, Inc.
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
Dana-Farber Cancer Institute
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Ossium Health, Inc.
SELECT-CAR-NK
Essen Biotech
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
St. Jude Children's Research Hospital
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
UNC Lineberger Comprehensive Cancer Center
Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
Case Comprehensive Cancer Center
Umbilical Cord Blood Transplantation From Unrelated Donors
University of Rochester
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL
University Health Network, Toronto
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
Case Comprehensive Cancer Center
Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
DALY II USA/ MB-CART2019.1 for DLBCL
Miltenyi Biomedicine GmbH
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Caribou Biosciences, Inc.
CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma
Affiliated Hospital to Academy of Military Medical Sciences
A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy
Affiliated Hospital of Nantong University
Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects with Relapsed/Refractory Lymphoma
Shanghai First Song Biotechnology Co., LTD
Combination of CAR-DC Vaccine and ICIs in Malignant Tumors
Chinese PLA General Hospital
A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL
Ruijin Hospital
Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies
The Affiliated People's Hospital of Ningbo University